The total return over the past 12 months is -75.96% vs. +16.94% for the S&P 500. So far it's up -52.48% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (76.01%) | (68.85%) | (64.15%) | (64.35%) | N/A | N/A |
| Total Return CAGR | (75.96%) | (68.83%) | (64.14%) | (64.35%) | N/A | N/A |
| Revenue CAGR | N/A | +131.07% | +64.60% | (13.17%) | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Traws Pharma, Inc. (TRAW)
| Year | Start price | End price | TRAW Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.13 | $0.54 | (52.48%) | +14.51% | (66.99%) |
| 2025 | $8.88 | $1.13 | (87.28%) | +17.72% | (105.00%) |
| 2024 | $18.75 | $8.88 | (52.65%) | +24.89% | (77.54%) |
| 2023 | $16.25 | $18.75 | +15.42% | +26.19% | (10.77%) |
| 2022 | $63.75 | $16.25 | (74.51%) | (18.17%) | (56.34%) |
| 2021 | $176.25 | $63.75 | (63.83%) | +28.74% | (92.57%) |
| 2020 | $142.50 | $176.25 | +23.68% | +18.37% | +5.31% |
| 2019 | $791.25 | $142.50 | (81.99%) | +31.22% | (113.21%) |
| 2018 | $8,437.50 | $791.25 | (90.62%) | (4.56%) | (86.06%) |
| 2017 | $12,768.75 | $8,437.50 | (33.92%) | +21.70% | (55.62%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
